The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and safety of IBI305 compared with bevacizumab in advanced non-squamous NSCLC patients as first-line treatment in a randomized, double-blind, phase III study.
 
Li Zhang
Research Funding - Lilly; Pfizer
 
Bin Wu
No Relationships to Disclose
 
Linian Huang
No Relationships to Disclose
 
Meiqi Shi
No Relationships to Disclose
 
Yunpeng Liu
No Relationships to Disclose
 
Yanqiu Zhao
No Relationships to Disclose
 
Lijun Wang
No Relationships to Disclose
 
Shun Lu
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Hutchison MediPharma; Roche
Speakers' Bureau - AstraZeneca; Lilly; Roche; Sanofi
Research Funding - AstraZeneca; Boehringer Ingelheim; Hutchison MediPharma; Roche
 
Gongyan Chen
No Relationships to Disclose
 
Baolan Li
No Relationships to Disclose
 
Conghua Xie
No Relationships to Disclose
 
Jian Fang
No Relationships to Disclose
 
Nong Yang
No Relationships to Disclose
 
Yiping Zhang
No Relationships to Disclose
 
Jiuwei Cui
No Relationships to Disclose
 
Yong Song
No Relationships to Disclose
 
Cuiying Zhang
No Relationships to Disclose
 
Xiaodong Mei
No Relationships to Disclose
 
Bangwei Cao
No Relationships to Disclose
 
Lan Yang
No Relationships to Disclose